ST250 as a Therapeutic Option for Head & Neck Reconstruction
Launched by ALAA EMARA · Aug 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called ST250, is exploring a new treatment option for patients who need surgery for tonsillitis, which is a condition that causes repeated infections in the tonsils. The study will test a special membrane called SupraThel 250, which is designed to help heal the tissues in the head and neck area after tonsil surgery. Researchers want to see if using this membrane can improve healing compared to letting the wounds heal on their own.
To participate in this trial, you must be between the ages of 65 and 74 and have had multiple episodes of tonsillitis. Unfortunately, children, pregnant or breastfeeding women, and those receiving chemotherapy or radiation therapy cannot join. If you are eligible and decide to participate, you will receive either the SupraThel 250 treatment or standard care after your tonsil surgery. This trial is currently not recruiting participants, but it aims to gather important information that could help improve recovery for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • recurrent episodes of tonsillar infection
- Exclusion Criteria:
- • children
- • pregnant/ breastfeeding women
- • patients undergoing chemo / radiotherapy
About Alaa Emara
Alaa Emara is a dedicated clinical trial sponsor committed to advancing medical research and innovation through rigorous and ethical study design. With a focus on enhancing patient outcomes, the organization collaborates with healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. Alaa Emara prioritizes compliance with regulatory standards and fosters a culture of transparency and integrity, ensuring that all research is conducted responsibly and with the utmost respect for participant safety. Through its efforts, Alaa Emara aims to contribute significantly to the development of new treatments and the improvement of healthcare practices globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stuttgart, Baden Wurttemberg, Germany
Patients applied
Trial Officials
Alaa Emara
Principal Investigator
Cairo University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported